BioPharma.
company in Jílové u Prahy, Czech Republic
- Reports this week
- 1
- Active events
- 2
- Connections
- 67
What's happening
Active this week
Earlier this month
-
Cantor Fitzgerald reiterated an overweight rating on BioPharma shares, reducing the target price and setting a buy rating.Some support5 reports
-
Drug trial results are impacting the valuation of BioPharma.Some support1 report
-
BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.Some support3 reports1 development inside
-
BioPharma and Milestone Pharmaceuticals are small-cap healthcare companies.Some support1 report
One to three months ago
-
The finance sector is encountering unique challenges related to biopharma, driven by the accelerating adoption of advanced technologies.Some support2 reports1 development inside
-
Definitive Healthcare launched its Turbo AI platform and noted improving activity within the biopharma sector.Some support1 report
Gone quiet
No new reports in 90+ days-
BioPharma appoints a new US head and secures US plasma supply, while Grifols reorganizes its operating model.Some support1 report
-
BioPharma organizations are targeted by the agreement in Santa Clara.Some support1 report1 development inside
-
A director of BioPharma purchased company shares on June 30, 2026.Some support1 report
-
BioPharma was listed on the electronic stock exchange on June 17, 2026.Some support1 report
-
BioPharma, led by Michael Breen, held meetings at a conference in New York City in September 2025.Some support1 report1 development inside
-
BioPharma announced results from San Francisco on August 15, 2025, with Michael Breen as Executive Chairman and CEO.Some support1 report
-
Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.Some support2 reports6 developments inside
-
Company announced trial initiation from San Francisco on August 11, 2025.Some support2 reports
-
CORT submitted an FDA application for relacorilant, while AI stocks continue to benefit from Trump-era tariffs.Some support2 reports
-
Ecolab's acquisition of Purolite is aimed at addressing the growing demand within the biopharma sector.Speculative1 report
-
Virtusa provides digital services to help biopharma clients digitize their value chain.Some support1 report
-
RAC provides modular hardware and Catalyst scheduling software to clients in the biopharma sector, including Ginkgo Bioworks.Some support1 report1 development inside
-
FDA decisions are noted to be driving momentum within the biopharma industry.Some support1 report
-
BioPharma and OncoX BioPharma signed a strategic licensing agreement for oncology development.Some support1 report
-
Richard Tobin cited positive margin mix from growth platforms for BioPharma.Some support1 report
-
ABVC licensed four IND-stage drug assets to OncoX BioPharma on August 1, 2025.Some support1 report
-
ClearPoint Neuro appointed Joe Burnett as President and CEO and formed new partnerships with BioPharma on August 13, 2025.Some support1 report
-
Companies FSS, Avantor, BioPharma, and Enova detailed their diverse business profiles, including financial services and mission-critical products.Some support2 reports3 developments inside
-
An AI assistant is being used to aid regulatory professionals within the biopharma industry.Some support2 reports
-
BioPharma commercialized its therapeutics in the United States on August 17, 2025.Some support1 report
-
BioPharma received a milestone payment for the Vitargus(R) licensing deal from ForSeeCon Eye Corporation.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around BioPharma this week
News at the entities that move BioPharma most-
FDA StructuralBMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.Moves BioPharma
-
Nasdaq StructuralIREN has listed on the Nasdaq stock exchange and secured a license for an AI campus to serve European customers.Moves BioPharma
-
Ecolab StructuralEcolab announced a $500M investment plan in Minnesota, approved by Eagan, demonstrating commitment to the state.Moves BioPharma
-
MarketBeat Mentioned togetherMarketBeat reported analyst recommendations for small-cap technology companies Energous Corporation and Magnachip Semiconductor.Moves BioPharma
-
Jefferies Financial Group OperationalJefferies Financial Group initiated analyst coverage on IperionX Limited Sponsored ADR stock on October 1, 2026.Moves BioPharma
-
Cantor Fitzgerald Mentioned togetherTD Cowen reaffirmed a buy rating while Cantor Fitzgerald downgraded monday.com Ltd. on October 6, 2026.Moves BioPharma
Connections
The 22 strongest of 67, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
BioPharma is a publicly traded company listed and traded on the Nasdaq stock exchange.
-
Christina Kay Structural
Christina Kay serves as Co-CEO of BioPharma.
-
FDA Structural
The FDA functions as the formal regulatory body responsible for reviewing, approving, and setting the market path for BioPharma products and applications.
-
Felipe Palacios Structural
Felipe Palacios holds a leadership position at BioPharma US.
-
Fresenius Kabi Structural
Fresenius Kabi employs the President of BioPharma, indicating a formal organizational link.
-
Ecolab Structural
Ecolab provides process development and specialized solutions to support BioPharma's operational needs.
-
Veeva Systems Operational
Veeva Systems actively secures contracts and achieves adoption within the BioPharma industry.
-
Sungkyunkwan University Operational
BioPharma and Sungkyunkwan University have formed a partnership for focused ultrasound market entry.
Show all 22 connections
-
Bruker Operational
BioPharma market demand and conditions directly influence the performance of Bruker's BioSpin segment.
-
MarketBeat Mentioned together
MarketBeat tracks and reports financial metrics, including average ratings and consensus targets, for BioPharma.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald has consistently maintained an overweight rating on the BioPharma sector.
-
Citigroup Mentioned together
Citigroup provides investment ratings and target price adjustments for BioPharma.
-
Jefferies Financial Group Operational
Jefferies Financial Group provided a target price for BioPharma.
-
GLP Operational
BioPharma and GLP have initiated a current statement of work for preclinical services.
-
Truist Financial Mentioned together
Truist Financial provided positive financial coverage, including raising price targets and issuing a buy rating, for BioPharma.
-
IQVIA Mentioned together
The relationship is based on a single snapshot labeling the companies as competitors in a specific geographic and industry context.
-
Santa Clara Shared context
BioPharma organizations are situated and targeted by agreements within the Santa Clara area.
-
Grifols Shared context
Both companies operate within the same highly regulated US life sciences market, specifically regarding plasma supply and operational models.
-
New York Shared context
BioPharma is located in New York.
-
James Huang Structural
James Huang holds a formal role as a director and shareholder in BioPharma.
-
Repligen Mentioned together
Both entities are mentioned in the context of general market trends and funding within the biopharma sector.
-
Erik Lundgren Mentioned together
No direct relationship between BioPharma and Erik Lundgren was observed in the provided evidence.
History
Events by the month they beganOctober 2026
3 eventsSeptember 2026
1 eventAugust 2026
1 eventShow 2 earlier months
July 2026
3 events- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- The finance sector is encountering unique challenges related to biopharma, driven by the accelerating adoption of advanced technologies.
- BioPharma appoints a new US head and secures US plasma supply, while Grifols reorganizes its operating model.
June 2026
21 events- Cantor Fitzgerald reiterated an overweight rating on BioPharma shares, reducing the target price and setting a buy rating.
- BioPharma organizations are targeted by the agreement in Santa Clara.
- A director of BioPharma purchased company shares on June 30, 2026.
- BioPharma was listed on the electronic stock exchange on June 17, 2026.
- BioPharma, led by Michael Breen, held meetings at a conference in New York City in September 2025.
- BioPharma announced results from San Francisco on August 15, 2025, with Michael Breen as Executive Chairman and CEO.
- Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.
- Company announced trial initiation from San Francisco on August 11, 2025.
- CORT submitted an FDA application for relacorilant, while AI stocks continue to benefit from Trump-era tariffs.
- Ecolab's acquisition of Purolite is aimed at addressing the growing demand within the biopharma sector.
- Virtusa provides digital services to help biopharma clients digitize their value chain.
- RAC provides modular hardware and Catalyst scheduling software to clients in the biopharma sector, including Ginkgo Bioworks.
- FDA decisions are noted to be driving momentum within the biopharma industry.
- BioPharma and OncoX BioPharma signed a strategic licensing agreement for oncology development.
- Richard Tobin cited positive margin mix from growth platforms for BioPharma.
- ABVC licensed four IND-stage drug assets to OncoX BioPharma on August 1, 2025.
- ClearPoint Neuro appointed Joe Burnett as President and CEO and formed new partnerships with BioPharma on August 13, 2025.
- Companies FSS, Avantor, BioPharma, and Enova detailed their diverse business profiles, including financial services and mission-critical products.
- An AI assistant is being used to aid regulatory professionals within the biopharma industry.
- BioPharma commercialized its therapeutics in the United States on August 17, 2025.
- BioPharma received a milestone payment for the Vitargus(R) licensing deal from ForSeeCon Eye Corporation.